WO2008096547A1 - 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物 - Google Patents

組織滞留性キトサンゲルを含有する抗腫瘍剤組成物 Download PDF

Info

Publication number
WO2008096547A1
WO2008096547A1 PCT/JP2008/000179 JP2008000179W WO2008096547A1 WO 2008096547 A1 WO2008096547 A1 WO 2008096547A1 JP 2008000179 W JP2008000179 W JP 2008000179W WO 2008096547 A1 WO2008096547 A1 WO 2008096547A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
accumulating
chitosan
chitosan gel
gel
Prior art date
Application number
PCT/JP2008/000179
Other languages
English (en)
French (fr)
Inventor
Masayuki Ishihara
Yasuhiro Kanatani
Yoshiharu Matahira
Hirofumi Yura
Original Assignee
Yaizu Suisankagaku Industry Co., Ltd.
Netech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yaizu Suisankagaku Industry Co., Ltd., Netech Inc. filed Critical Yaizu Suisankagaku Industry Co., Ltd.
Priority to JP2008557028A priority Critical patent/JPWO2008096547A1/ja
Priority to US12/525,809 priority patent/US20100093660A1/en
Priority to EP08710333A priority patent/EP2110131A1/en
Publication of WO2008096547A1 publication Critical patent/WO2008096547A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明は、組織滞留性キトサンゲルの抗腫瘍活性を初めて見出したことに基づき、組織滞留性キトサンゲルを含有する抗腫瘍剤組成物を提供する。本発明の組織滞留性キトサンゲルは、糖鎖を導入したキトサン誘導体を基本とし、その糖鎖含有キトサン誘導体に光反応性基を更に導入して光架橋させたキトサンゲル、あるいは、糖鎖含有キトサン誘導体と他の物質、例えば酸性多糖類とのポリイオンコンプレックスからなるキトサンゲルが好ましい。本発明の抗腫瘍剤組成物は、腫瘍の近傍に配置しておくだけで、腫瘍組織に接触することなく腫瘍成長を抑制できる。
PCT/JP2008/000179 2007-02-07 2008-02-07 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物 WO2008096547A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2008557028A JPWO2008096547A1 (ja) 2007-02-07 2008-02-07 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物
US12/525,809 US20100093660A1 (en) 2007-02-07 2008-02-07 Anti-tumor composition comprising tissue-accumulating chitosan gel
EP08710333A EP2110131A1 (en) 2007-02-07 2008-02-07 Anti-tumor composition comprising tissue-accumulating chitosan gel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-027731 2007-02-07
JP2007027731 2007-02-07

Publications (1)

Publication Number Publication Date
WO2008096547A1 true WO2008096547A1 (ja) 2008-08-14

Family

ID=39681458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000179 WO2008096547A1 (ja) 2007-02-07 2008-02-07 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物

Country Status (5)

Country Link
US (1) US20100093660A1 (ja)
EP (1) EP2110131A1 (ja)
JP (1) JPWO2008096547A1 (ja)
CN (1) CN101663038A (ja)
WO (1) WO2008096547A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2454221A (en) * 2007-11-01 2009-05-06 Mohamed Abdelhafez El-Far Chemically modified chitosan as an anticancer agent
JP2013523411A (ja) * 2010-04-15 2013-06-17 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド 抗凝固剤を使用しない透析システムおよび抗凝固剤を使用しない透析方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11773188B2 (en) 2012-01-20 2023-10-03 Immunophotonics, Inc Chitosan-derived compositions
US20160151286A1 (en) * 2013-05-29 2016-06-02 Therakine Biodelivery Gmbh Hydrophilic Microparticles, Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery of A Drug-Delivery Composition
US20190002594A1 (en) 2014-07-16 2019-01-03 Immunophotonics, Inc. Chitosan-Derived Compositions
AU2021324708A1 (en) * 2020-08-14 2023-03-09 Mochida Pharmaceutical Co., Ltd. Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same
WO2023148351A1 (en) * 2022-02-03 2023-08-10 Gcs Institut De Cancerologie Strasbourg Europe Pharmaceutical formulation for subcutaneous administration of proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
JPH09103481A (ja) 1989-05-11 1997-04-22 Kanegafuchi Chem Ind Co Ltd 生体適合性に優れた表面を有する医療用具およびその製造方法
JPH10120705A (ja) 1996-10-15 1998-05-12 Neetec:Kk 合成アミノ糖類誘導体及びその製造方法
WO2000027889A1 (fr) 1998-11-10 2000-05-18 Netech Inc. Derive fonctionnel du chitosane
WO2003090765A1 (fr) 2002-04-23 2003-11-06 Netech Inc. Compositions medicinales contenant un derive de chitosan photo-reticulable
WO2005025538A1 (ja) 2003-09-08 2005-03-24 Netech Inc. 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60323943D1 (de) * 2002-02-21 2008-11-20 Encelle Inc Immobilisierte bioaktive hydrogel matrizen für oberflächenbeschichtungen
EP1635782A1 (de) * 2003-05-24 2006-03-22 JUVENA (International) AG Gewebekulturmedien als bestandteil von kosmetika

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09103481A (ja) 1989-05-11 1997-04-22 Kanegafuchi Chem Ind Co Ltd 生体適合性に優れた表面を有する医療用具およびその製造方法
JPH04334322A (ja) * 1991-05-09 1992-11-20 Unitika Ltd 抗腫瘍剤
JPH10120705A (ja) 1996-10-15 1998-05-12 Neetec:Kk 合成アミノ糖類誘導体及びその製造方法
WO2000027889A1 (fr) 1998-11-10 2000-05-18 Netech Inc. Derive fonctionnel du chitosane
WO2003090765A1 (fr) 2002-04-23 2003-11-06 Netech Inc. Compositions medicinales contenant un derive de chitosan photo-reticulable
WO2005025538A1 (ja) 2003-09-08 2005-03-24 Netech Inc. 糖鎖含有キトサン誘導体及びグリコサミノグリカンを含有する医療用組成物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Applications of Chitins and Chitosans", 20 February 1990, GIHODO SHUPPAN KK, pages: 53 - 56
"colloidal titration method" described in "Health Foods Standard and Criterion (No. 4)", JAPAN HEALTH FOOD AND NUTRITION FOOD ASSOCIATION, 1996, pages 55
"Journal of Polymer Science: Polymer Chemistry Edition", vol. 20, 1982, pages: 1419 - 1432
J. E. HODGE; B. T. HOFREITER: "Methods in Carbohydrate Chemistry", vol. 1, 1962, ACADEMIC PRESS, pages: 388
K. OBARA ET AL., CONTROL RELEASE, vol. 110, 2005, pages 79 - 89
K. ONO ET AL., BR. J. CANCER, vol. 86, 2002, pages 1803 - 1812
OBARA K. ET AL.: "Controlled release of paclitaxel from photocrosslinked chitosan hydrogels and its subsequent effect on subcutaneous tumor growth in mice", JOURNAL OF CONTROLLED RELEASE, vol. 110, no. 1, 2005, pages 79 - 89, XP005192554 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2454221A (en) * 2007-11-01 2009-05-06 Mohamed Abdelhafez El-Far Chemically modified chitosan as an anticancer agent
JP2013523411A (ja) * 2010-04-15 2013-06-17 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド 抗凝固剤を使用しない透析システムおよび抗凝固剤を使用しない透析方法

Also Published As

Publication number Publication date
EP2110131A1 (en) 2009-10-21
CN101663038A (zh) 2010-03-03
JPWO2008096547A1 (ja) 2010-05-20
US20100093660A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2008096547A1 (ja) 組織滞留性キトサンゲルを含有する抗腫瘍剤組成物
WO2007126727A3 (en) WATER SOLUBLE β-GLUCAN, GLUCOSAMINE, AND N-ACETYLGLUCOSAMINE COMPOSITIONS AND METHODS FOR MAKING THE SAME
WO2007079448A3 (en) Three component carbohydrate vaccine
WO2007100922A3 (en) Methods of making polymeric articles and polymeric articles formed thereby
WO2008057867A3 (en) Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
WO2005118008A3 (en) Compositions and articles containing a crosslinked polymer matrix and an immobilized active liquid, as well as methods of making and using the same
WO2006083991A3 (en) Fiber-reinforced composite absorbable endoureteral stent
WO2008036206A3 (en) Copolymer-bioceramic composite implantable medical devices
WO2007127890A3 (en) Structured films having acoustical absorbance properties
WO2007113222A3 (en) Immunogenic composition
WO2009042962A3 (en) Antidotes for factor xa inhibitors and methods of using the same
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
WO2006128167A3 (en) Optical coherence tomographic detection of cells and compositions
WO2008021156A3 (en) Antibodies to il-17a
WO2010039626A3 (en) Methods to communicate a timestamp to a storage system
WO2007079147A3 (en) A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2006023397A3 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
WO2008093303A3 (en) Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
WO2012122404A3 (en) Micellar polysiloxane enzyme immobilization materials
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2009004629A3 (en) A method for decreasing symptoms of alcohol consumption
WO2010078036A3 (en) Biocompatible polysaccharide-based hydrogels
WO2009149030A3 (en) Oral care compositions and methods
WO2010048389A3 (en) Vaginal pellets comprising debranched starch
WO2008063759A3 (en) A method of increasing retention, survival and proliferation of transplanted cells in vivo

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880004012.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08710333

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008557028

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008710333

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12525809

Country of ref document: US